ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133,387 | -70.6% | 19,473 | -68.2% | 0.51% | -7.8% |
| Q4 2018 | $453,000 | -21.5% | 61,264 | +54.1% | 0.55% | +3.2% |
| Q3 2018 | $577,000 | +47.9% | 39,755 | +103.7% | 0.53% | +286.2% |
| Q2 2018 | $390,000 | +5.4% | 19,514 | -7.7% | 0.14% | -65.7% |
| Q1 2018 | $370,000 | -16.7% | 21,142 | +17.5% | 0.40% | -25.6% |
| Q4 2017 | $444,000 | +68.8% | 17,994 | +76.8% | 0.54% | +101.5% |
| Q3 2017 | $263,000 | -4.4% | 10,176 | +0.4% | 0.27% | -37.5% |
| Q2 2017 | $275,000 | -30.4% | 10,138 | -23.6% | 0.43% | -62.0% |
| Q1 2017 | $395,000 | +10.0% | 13,263 | +0.2% | 1.13% | -7.9% |
| Q4 2016 | $359,000 | – | 13,241 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |